Search results
Roche wins FDA OK for Alecensa in early lung cancer
BioPharma Dive via Yahoo Finance· 7 hours agoand Daiichi Sankyo, could be approved by the end of the year. Roche’s drug is for the estimated 5% of lung cancer patients with ALK mutations. Alecensa...
The Cream Of The Crop: 5 Biotechs That Outrank Most Stocks
Investor's Business Daily· 4 hours agoFurther, a depression treatment failed to meet the goal of a proof-of-concept study. Neurocrine...
Analysts Expect Moderna's First-Quarter Sales To Plummet 95% — Is Moderna Stock A Sell?
Investor's Business Daily· 4 hours agoThe company expects to gain Food and Drug Administration approval in the first half of the year, vs....
Is Pfizer Stock A Sell As Shares Hit A 9-Year Low Amid The Search For Its Next Big Break?
Investor's Business Daily· 1 day agoPfizer is now angling for Adcentris' eighth Food and Drug Administration approval. In fact, < ...
FDA expands Pfizer boosters for more teens as omicron surges
AOL· 10 hours agoThe U.S. is expanding COVID-19 boosters as it confronts the omicron surge, with the Food and Drug Administration allowing ...
Pfizer to seek approval for RSV vaccine for people as young as 18 - Boston News, Weather, Sports |...
7 News Boston· 1 week agoThe company said it would submit the information to the US Food and Drug Administration for...
Pfizer's RSV vaccine shows potential to protect high-risk adults ages 18-59, widening possible use
CNBC· 1 week agoThe initial data suggests that Pfizer's shot, known as Abrysvo, could help protect a far wider...
Pfizer RSV Vaccine Could Get Wider Use. New Study Suggests a Benefit For All Adults.
Barrons.com· 1 week agoFEATURE Pfizer said early Tuesday that it will ask the Food and Drug Administration to expand the...
Paxlovid COVID Treatment Is Most Beneficial for Unvaccinated People with Risk Factors. Others May...
Scientific American· 7 days agoThe novel antiviral drug Paxlovid swiftly entered the U.S. pharmaceutical market in late 2021 as an...
Pfizer RSV shot meets goals in trial of high-risk adults under age 60
Reuters via AOL· 1 week agoPfizer said on Tuesday its respiratory syncytial virus (RSV) vaccine Abrysvo was well tolerated and...